Symbols / EVMN Stock $22.17 -4.56% Evommune, Inc.
EVMN (Stock) Chart
Stock Fundamentals
|
|
|
|
|
|
About
Official websiteEvommune, Inc. operates as a clinical-stage biotechnology company in the United States. The company develops therapies that target key drivers of chronic inflammatory diseases, with initial clinical development programs focusing on chronic spontaneous urticaria, atopic dermatitis, and ulcerative colitis. Its products include EVO756 for the treatment of CSU and AD; and EVO301 for the treatment of AD and UC. The company was incorporated in 2020 and is based in Palo Alto, California.
Ratings
Current target
$22.17
Low
$50.00
High
$55.00
Mean
$52.25
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-05-26 | reit | HC Wainwright & Co. | Buy → Buy | $50 |
| 2026-05-11 | main | Morgan Stanley | Overweight → Overweight | $55 |
| 2026-04-10 | reit | RBC Capital | Outperform → Outperform | $48 |
| 2026-03-18 | main | HC Wainwright & Co. | Buy → Buy | $50 |
| 2026-03-18 | init | Clear Street | — → Buy | $53 |
| 2026-02-10 | main | HC Wainwright & Co. | Buy → Buy | $65 |
| 2026-01-22 | init | Oppenheimer | — → Outperform | $42 |
| 2026-01-08 | init | Raymond James | — → Strong Buy | $40 |
| 2026-01-06 | init | HC Wainwright & Co. | — → Buy | $35 |
| 2025-12-01 | init | William Blair | — → Outperform | — |
| 2025-12-01 | init | Cantor Fitzgerald | — → Overweight | — |
| 2025-12-01 | init | Morgan Stanley | — → Overweight | $36 |
| 2025-12-01 | init | Leerink Partners | — → Outperform | $42 |
| 2025-12-01 | init | Evercore ISI Group | — → Outperform | $40 |
- Insider Sale: Chief Business & Legal Officer of $EVMN Sells 14,223 Shares - Quiver Quantitative ue, 02 Jun 2026 00
- Evommune (EVMN) officer exercises options and sells 14,223 shares under 10b5-1 plan - Stock Titan ue, 02 Jun 2026 00
- Evommune (EVMN) CFO sells 18,175 shares under 10b5-1 plan - Stock Titan Mon, 01 Jun 2026 23
- symbol__ Stock Quote Price and Forecast - CNN Sun, 19 Oct 2025 16
- 15,000-Share Rule 144 Notice for EVMN (EVMN) by Morgan Stanley - Stock Titan Mon, 01 Jun 2026 20
- Companies Like Evommune (NYSE:EVMN) Are In A Position To Invest In Growth - Yahoo Finance Mon, 11 May 2026 07
- H.C. Wainwright Maintains Evommune(EVMN.US) With Buy Rating, Maintains Target Price $50 - Moomoo ue, 26 May 2026 10
- H.C. Wainwright reiterates Evommune stock rating on trial progress By Investing.com - Investing.com Nigeria ue, 26 May 2026 12
- Evommune's EVO301 Phase 2a Data Drives 70% Stock Surge (NYSE:EVMN) - Seeking Alpha Wed, 11 Feb 2026 08
- What is the current Price Target and Forecast for Evommune Inc. (EVMN) - Zacks Investment Research Sun, 22 Feb 2026 10
- This Biotech Stock Nearly Doubled In Value Today Morning – What’s Driving Investor Optimism? - Stocktwits ue, 10 Feb 2026 13
- EVMN Stock Price and Chart — NYSE:EVMN - TradingView Wed, 05 Nov 2025 08
- EVOMMUNE INC EVMN ) Stock Price Today & Analysis - Gotrade ue, 16 Dec 2025 21
- Evommune (EVMN) Stock Price, News & Analysis - MarketBeat Fri, 21 Nov 2025 04
- $EVMN stock is up 9% today. Here's what we see in our data. - Quiver Quantitative hu, 29 Jan 2026 08
Insider Transactions
Financials
Statement View
| Line Item | Trend | 2025-12-31 |
|---|---|---|
| Total Revenue |
|
13.00
|
| Operating Revenue |
|
13.00
|
| Operating Expense |
|
94.07
|
| Research And Development |
|
74.04
|
| Selling General And Administration |
|
20.03
|
| General And Administrative Expense |
|
20.03
|
| Salaries And Wages |
|
12.54
|
| Other Gand A |
|
7.48
|
| Total Expenses |
|
94.07
|
| Operating Income |
|
-81.07
|
| Total Operating Income As Reported |
|
-81.07
|
| EBITDA |
|
-79.68
|
| Normalized EBITDA |
|
-88.61
|
| Reconciled Depreciation |
|
1.39
|
| EBIT |
|
-81.07
|
| Total Unusual Items |
|
8.93
|
| Total Unusual Items Excluding Goodwill |
|
8.93
|
| Net Income |
|
-68.87
|
| Pretax Income |
|
-68.87
|
| Net Non Operating Interest Income Expense |
|
3.32
|
| Net Interest Income |
|
3.32
|
| Interest Income Non Operating |
|
3.32
|
| Interest Income |
|
3.32
|
| Other Income Expense |
|
8.88
|
| Other Non Operating Income Expenses |
|
-0.05
|
| Gain On Sale Of Security |
|
8.93
|
| Tax Rate For Calcs |
|
0.00
|
| Tax Effect Of Unusual Items |
|
0.00
|
| Net Income Including Noncontrolling Interests |
|
-68.87
|
| Net Income From Continuing Operation Net Minority Interest |
|
-68.87
|
| Net Income From Continuing And Discontinued Operation |
|
-68.87
|
| Net Income Continuous Operations |
|
-68.87
|
| Normalized Income |
|
-77.80
|
| Net Income Common Stockholders |
|
-68.87
|
| Otherunder Preferred Stock Dividend |
|
0.00
|
| Diluted EPS |
|
—
|
| Basic EPS |
|
—
|
| Basic Average Shares |
|
—
|
| Diluted Average Shares |
|
—
|
| Diluted NI Availto Com Stockholders |
|
-68.87
|
| Line Item | Trend | 2025-12-31 |
|---|---|---|
| Total Assets |
|
224.95
|
| Current Assets |
|
153.48
|
| Cash Cash Equivalents And Short Term Investments |
|
149.20
|
| Cash And Cash Equivalents |
|
44.06
|
| Other Short Term Investments |
|
105.14
|
| Other Current Assets |
|
4.28
|
| Total Non Current Assets |
|
71.47
|
| Net PPE |
|
2.46
|
| Gross PPE |
|
4.02
|
| Accumulated Depreciation |
|
-1.56
|
| Properties |
|
0.00
|
| Machinery Furniture Equipment |
|
1.99
|
| Construction In Progress |
|
0.04
|
| Other Properties |
|
1.47
|
| Leases |
|
0.53
|
| Investments And Advances |
|
67.49
|
| Other Non Current Assets |
|
1.52
|
| Total Liabilities Net Minority Interest |
|
19.38
|
| Current Liabilities |
|
17.91
|
| Payables And Accrued Expenses |
|
12.37
|
| Payables |
|
7.76
|
| Accounts Payable |
|
7.76
|
| Current Accrued Expenses |
|
4.61
|
| Pensionand Other Post Retirement Benefit Plans Current |
|
4.93
|
| Current Debt And Capital Lease Obligation |
|
0.24
|
| Current Capital Lease Obligation |
|
0.24
|
| Current Deferred Liabilities |
|
0.00
|
| Current Deferred Revenue |
|
0.00
|
| Other Current Liabilities |
|
0.36
|
| Total Non Current Liabilities Net Minority Interest |
|
1.47
|
| Long Term Debt And Capital Lease Obligation |
|
1.47
|
| Long Term Capital Lease Obligation |
|
1.47
|
| Preferred Securities Outside Stock Equity |
|
0.00
|
| Stockholders Equity |
|
205.57
|
| Common Stock Equity |
|
205.57
|
| Capital Stock |
|
0.00
|
| Common Stock |
|
0.00
|
| Share Issued |
|
31.52
|
| Ordinary Shares Number |
|
31.52
|
| Additional Paid In Capital |
|
426.65
|
| Retained Earnings |
|
-221.09
|
| Total Equity Gross Minority Interest |
|
205.57
|
| Total Capitalization |
|
205.57
|
| Working Capital |
|
135.57
|
| Invested Capital |
|
205.57
|
| Total Debt |
|
1.71
|
| Capital Lease Obligations |
|
1.71
|
| Net Tangible Assets |
|
205.57
|
| Tangible Book Value |
|
205.57
|
| Held To Maturity Securities |
|
67.49
|
| Investmentin Financial Assets |
|
67.49
|
| Line Item | Trend | 2025-12-31 |
|---|---|---|
| Operating Cash Flow |
|
-76.44
|
| Cash Flow From Continuing Operating Activities |
|
-76.44
|
| Net Income From Continuing Operations |
|
-68.87
|
| Depreciation Amortization Depletion |
|
1.39
|
| Depreciation And Amortization |
|
1.39
|
| Other Non Cash Items |
|
-1.77
|
| Stock Based Compensation |
|
5.86
|
| Operating Gains Losses |
|
-8.93
|
| Gain Loss On Investment Securities |
|
-8.93
|
| Change In Working Capital |
|
-4.12
|
| Change In Prepaid Assets |
|
-2.37
|
| Change In Payables And Accrued Expense |
|
1.98
|
| Change In Accrued Expense |
|
2.82
|
| Change In Payable |
|
-0.84
|
| Change In Account Payable |
|
-0.84
|
| Change In Other Working Capital |
|
-3.00
|
| Change In Other Current Liabilities |
|
-0.73
|
| Investing Cash Flow |
|
-115.31
|
| Cash Flow From Continuing Investing Activities |
|
-115.31
|
| Net PPE Purchase And Sale |
|
-0.23
|
| Purchase Of PPE |
|
-0.23
|
| Capital Expenditure |
|
-0.23
|
| Net Investment Purchase And Sale |
|
-115.07
|
| Purchase Of Investment |
|
-199.17
|
| Sale Of Investment |
|
84.10
|
| Financing Cash Flow |
|
220.76
|
| Cash Flow From Continuing Financing Activities |
|
220.76
|
| Net Issuance Payments Of Debt |
|
-0.37
|
| Repayment Of Debt |
|
-0.37
|
| Long Term Debt Payments |
|
-0.37
|
| Net Long Term Debt Issuance |
|
-0.37
|
| Proceeds From Stock Option Exercised |
|
157.29
|
| Net Other Financing Charges |
|
-1.38
|
| Changes In Cash |
|
29.02
|
| Beginning Cash Position |
|
16.46
|
| End Cash Position |
|
45.48
|
| Free Cash Flow |
|
-76.68
|
| Interest Paid Supplemental Data |
|
0.01
|
| Issuance Of Capital Stock |
|
65.23
|
| Net Preferred Stock Issuance |
|
65.23
|
| Preferred Stock Issuance |
|
65.23
|
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
- 42026-06-01 View
- 42026-06-01 View
- 10-Q2026-05-07 View
- 8-K2026-05-07 View
- 42026-04-17 View
- 42026-04-17 View
- 42026-04-17 View
- 42026-04-17 View
- 42026-04-17 View
- 42026-04-17 View
- 8-K2026-04-13 View
- 10-K2026-03-05 View
- 8-K2026-03-05 View
- 42026-02-19 View
- 42026-02-18 View
- 42026-02-17 View
- 8-K2026-02-13 View
- 8-K2026-02-10 View
- 42025-12-22 View
- 42025-12-19 View
Trades
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|
Posts
| Published | Title | Author | Category |
|---|